First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How TRAX compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 17.6% | +107.2 pp | +1139.8 pp | |
| LTM Mar 2026 | -961.9% | -168.3 pp | -673.9 pp | |
| FY2025 | -4974.7% | — | — | |
| LTM Sep 2026 | -7488.4% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
CLYMClimb Bio, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TRAX) | -2968.3% | -30.6 pp | +233.0 pp | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 152.35M | 139.61M |
| Gross Profit | 0 | (152.35M) | (139.61M) |
| Gross Margin | — | — | — |
| Research & Development | 97.59M | 152.35M | 139.61M |
| Selling, General & Admin | 20.87M | 28.76M | 39.39M |
| Operating Expenses | 118.46M | 28.76M | 39.39M |
| Depreciation & Amortization | 2.38M | 2.4M | 559K |
| EBITDA | (116.09M) | (178.7M) | (178.45M) |
| EBITDA Margin | — | — | — |
| Operating Income | (118.46M) | (181.1M) | (179.01M) |
| Operating Margin | — | — | — |
| Interest Income | 12.31M | 17.38M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 12.31M | 17.4M | 12.92M |
| Income Before Tax | (106.15M) | (163.71M) | (166.09M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Net Margin | — | — | — |
| EPS (Basic) | (3.05) | 0.00 | 0.00 |
| EPS (Diluted) | (3.05) | 0.00 | 0.00 |
| Weighted Avg Shares | 34.75M | 0 | 0 |
| Weighted Avg Shares (Diluted) | 34.75M | 0 | 0 |
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.